Cargando…
Population-based recurrence rates among older women with HR-positive, HER2-negative early breast cancer: Clinical risk factors, frailty status, and differences by race
BACKGROUND: Multiple independent risk factors are associated with the prognosis of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC), the most common BC subtype. This study describes U.S. population-based recurrence rates among older, resec...
Autores principales: | Zhou, Jifang, Cueto, Jenilee, Ko, Naomi Y., Hoskins, Kent F., Nabulsi, Nadia A., Asfaw, Alemseged A., Hubbard, Colin C., Mitra, Debanjali, Calip, Gregory S., Law, Ernest H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379689/ https://www.ncbi.nlm.nih.gov/pubmed/34419726 http://dx.doi.org/10.1016/j.breast.2021.08.005 |
Ejemplares similares
-
Impact of time to distant recurrence on breast cancer-specific mortality in hormone receptor-positive breast cancer
por: Calip, Gregory S., et al.
Publicado: (2022) -
Health-related Quality of Life in Hormone Receptor-Positive Early
Breast Cancer: Analyses From the Surveillance, Epidemiology, and End Results
Medicare Health Outcomes Survey
por: Nabulsi, Nadia A, et al.
Publicado: (2022) -
Physical functioning, frailty and risks of locally-advanced breast cancer among older women
por: Coleman, Chandler, et al.
Publicado: (2022) -
Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis
por: Salvo, Elizabeth M., et al.
Publicado: (2021) -
Real-World Palbociclib Use in HR+/HER2− Advanced Breast Cancer in Canada: The IRIS Study
por: Mycock, Katie, et al.
Publicado: (2021)